Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 – For Medical Students & Physicians A complete 20-lesson, 300-page Chinese HSK 1 course with a companion app in 21 languages — free forever. Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Nuclear Medicine

Free Subscription Articles published in Lancet Retrieve available abstracts of 11 articles: HTML format

Single Articles

November 2025
1. VAN DER BIJL P, Gulati M, Saraste A, Marwick T, et al
   Contemporary, non-invasive imaging diagnosis of chronic coronary artery disease.
   Lancet. 2025;406:2577-2587.
   PubMed     Abstract available
   
   
   September 2025
2. FRISONI GB, Hansson O, Nichols E, Garibotto V, et al
   New landscape of the diagnosis of Alzheimer's disease.
   Lancet. 2025;406:1389-1407.
   PubMed     Abstract available
   
   
   April 2025
3. FERDINANDUS J, Schneider G, Borchmann P
   PET evaluation in Hodgkin lymphoma: when to change treatment - Authors' reply.
   Lancet. 2025;405:1145.
   PubMed    
   
   
   
4. SHIMAZU Y
   PET evaluation in Hodgkin lymphoma: when to change treatment.
   Lancet. 2025;405:1144-1145.
   PubMed    
   
   
   March 2025
5. PEREZ-GARCIA JM, Gebhart G, Rodriguez-Morato J, Llombart-Cussac A, et al
   Neoadjuvant therapy in HER2-positive breast cancer and interim PET - Authors' reply.
   Lancet. 2025;405:1055-1056.
   PubMed    
   
   
   
6. HINDIE E, Groheux D
   Neoadjuvant therapy in HER2-positive breast cancer and interim PET.
   Lancet. 2025;405:1054-1055.
   PubMed    
   
   
   July 2024
7. EVENS AM
   Enhancing the treatment landscape: PET-guided BrECADD for advanced-stage, classical Hodgkin lymphoma.
   Lancet. 2024;404:312-313.
   PubMed    
   
   
   
8. BORCHMANN P, Ferdinandus J, Schneider G, Moccia A, et al
   Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.
   Lancet. 2024 Jul 3:S0140-6736(24)01315-1. doi: 10.1016/S0140-6736(24)01315.
   PubMed     Abstract available
   
   
   April 2024
9. PEREZ-GARCIA JM, Cortes J, Ruiz-Borrego M, Colleoni M, et al
   3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
   Lancet. 2024 Apr 3:S0140-6736(24)00054-0. doi: 10.1016/S0140-6736(24)00054.
   PubMed     Abstract available
   
   
   February 2024
10. BAYAS A, Menacher M, Lapa C, Tappe D, et al
    (18)fluorodeoxyglucose PET/CT as possible early diagnostic tool preceding MRI changes in Borna disease virus 1 encephalitis.
    Lancet. 2024;403:665-666.
    PubMed    
    
    
    December 2023
11. TSAI CJ, Yang JT, Shaverdian N, Patel J, et al
    Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomi
    Lancet. 2023 Dec 14:S0140-6736(23)01857-3. doi: 10.1016/S0140-6736(23)01857.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Nuclear Medicine is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum